Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: The VS411 model HIV/AIDS

British Journal of Pharmacology

Volumn 161, Issue 4, 2010, Pages 830-843

  De Forni, D ^a   Stevens, M R ^b   Lori, F ^a  

^a ViroStatics Srl   (Italy)

^b ViroStatics   (United States)

Author keywords

antiviral; AV HALT; bioavailability; C max; didanosine; hydroxyurea; hyper activation; pharmacokinetic; phase I; VS411

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; DIDANOSINE PLUS HYDROXYUREA; HYDROXYUREA; UNCLASSIFIED DRUG; VIDEX EC; VS 411;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIDANOSINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FASTING; HUMANS; HYDROXYUREA; LEAST-SQUARES ANALYSIS; NUCLEIC ACID SYNTHESIS INHIBITORS; PILOT PROJECTS;

EID: 77957229480     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00940.x     Document Type: Article

References (54)

1. Alpha (1996). The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee. AIDS 10 : 867 880.
2. Ameisen JC, Capron A (1991). Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 12 : 102 105.
3. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F et al. (1996). Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 29 : 111 113. (Pubitemid 26094529)
4. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S et al. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12 : 1365 1371. (Pubitemid 44924494)
5. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV et al. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332 : 1317 1322.
6. Damle BD, Yan JH, Behr D, O'Mara E, Nichola P, Kaul S et al. (2002). Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 42 : 419 427. (Pubitemid 34259776)
7. Davies SC, Gilmore A (2003). The role of hydroxyurea in the management of sickle cell disease. Blood Rev 17 : 99 109. (Pubitemid 36372974)
8. De Boer RJ, Boucher CA, Perelson AS (1998). Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 12 : 1567 1570.
9. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM (1999). Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13 : 473 478.
10. Donehower RC (1992). An overview of the clinical experience with hydroxyurea. Semin Oncol 19 : 11 19.
11. Douek DC (2003). Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 5 : 172 177.
12. Electronic Source: Bristol-Myers-Squibb (August 2006). Videx (didanosine). http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/ 020154s50,20155s39,20156s40,21183s16lbl.pdf (accessed 27 July 2006).
13. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C et al. (1995). Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1 : 129 134.
14. Foli A, Lori F, Tinelli C, Minoli L, Lisziewicz J (1997). Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antivir Ther 2 : 31 38. (Pubitemid 27232592)
15. Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y et al. (2004). Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 20 : 916 926. (Pubitemid 39369697)
16. Gao WY, Cara A, Gallo RC, Lori F (1993). Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 90 : 8925 8928. (Pubitemid 23306423)
17. Gao WY, Johns DG, Mitsuya H (1994). Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′- dideoxynucleosides. Mol Pharmacol 46 : 767 772. (Pubitemid 24334770)
18. Gao WY, Johns DG, Chokekuchai S, Mitsuya H (1995). Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′- dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 92 : 8333 8337.
19. Gatti G (2001). The relationship between systemic exposure to indinavir and response (virologic efficacy and renal toxicity). In 41st Interscience Conference on Antimicrobial Agents and chemotherapy, Chicago, IL.
20. Grossman Z, Paul WE (2000). The impact of HIV on naive T-cell homeostasis. Nat Med 6 : 976 977.
21. Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P et al. (2001). Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 15 : 1379 1388. (Pubitemid 32662289)
22. Hellerstein MK, Hoh RA, Hanley MB, Cesar D, Lee D, Neese RA et al. (2003). Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 112 : 956 966. (Pubitemid 38063753)
23. Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E et al. (2003). Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 100 : 4179 4184. (Pubitemid 36418177)
24. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H et al. (2003). T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187 : 1534 1543. (Pubitemid 36578959)
25. Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M et al. (1995). A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. AIDS 9 : 463 469.
26. Johns DG, Gao WY (1998). Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 55 : 1551 1556.
27. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A et al. (2003). CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163 : 2187 2195. (Pubitemid 37248783)
28. Kelly LM, Lisziewicz J, Lori F (2004). 'Virostatics' as a potential new class of HIV drugs. Curr Pharm Des 10 : 4103 4120.
29. Korin YD, Zack JA (1998). Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72 : 3161 3168.
30. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y et al. (2005). Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 : 1148 1152. (Pubitemid 40663495)
31. Lisziewicz J, Foli A, Wainberg M, Lori F (2003). Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf 26 : 605 624. (Pubitemid 36871835)
32. Lori F, Hall L, Lusso P, Popovic M, Markham P, Franchini G et al. (1992). Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. J Virol 66 : 5553 5560.
33. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J et al. (1994). Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266 : 801 805. (Pubitemid 24359288)
34. Lori F, Gallo RC, Malykh A, Cara A, Romano J, Markham P et al. (1997a). Didanosine but not high doses of hydroxyurea rescue pigtail macaque from a lethal dose of SIV (smmpbj14). AIDS Res Hum Retroviruses 13 : 1083 1088. (Pubitemid 27355737)
35. Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L et al. (1997b). Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 13 : 1403 1409. (Pubitemid 27460837)
36. Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N et al. (2005a). Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS 19 : 1173 1181. (Pubitemid 41059258)
37. Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P et al. (2005b). Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses 21 : 263 272. (Pubitemid 40632358)
38. Lotsch J, Harder S, Sturmer M, Doerr HW, Geisslinger G, Staszewski S et al. (2007). Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother 51 : 3264 3272. (Pubitemid 350067539)
39. McCune JM (2001). The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410 : 974 979.
40. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR (1994). Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 91 : 11017 11021. (Pubitemid 24985072)
41. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15 : 71 75. (Pubitemid 32055781)
42. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F (1992). Programmed death of T cells in HIV-1 infection. Science 257 : 217 219.
43. Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S et al. (1997). A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 175 : 801 806. (Pubitemid 27142951)
44. Navarra P, Preziosi P (1999). Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29 : 249 255. (Pubitemid 29158970)
45. Ravot E, Lisziewicz J, Lori F (1999). New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide. Drugs 58 : 953 963. (Pubitemid 30055040)
46. Reisler RB, Murphy RL, Redfield RR, Parker RA (2005). Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 39 : 159 166.
47. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC et al. (1998). A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 12 : F71 F77. (Pubitemid 28241394)
48. Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH (1991). Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 50 : 503 507.
49. Smith CH (1999). Use of hydroxyurea in psoriasis. Clin Exp Dermatol 24 : 2 6.
50. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J 9 : 1551 1560. (Pubitemid 20137012)
51. Vila J, Nugier F, Bargues G, Vallet T, Peyramond D, Hamedi-Sangsari F et al. (1997). Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350 : 635 636. (Pubitemid 27367799)
52. Yarbro JW (1992). Mechanism of action of hydroxyurea. Semin Oncol 19 : 1 10.
53. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS (1990). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 : 213 222. (Pubitemid 20149353)
54. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS et al. (1986). Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 231 : 850 853. (Pubitemid 16213045)